 TRACON Pharmaceuticals Inc NASDAQ:TCON says the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that the trial will proceed as planned following the review of safety data from more than 20 patients enrolled so far. The company said the safety data reviewed included data from more than 10 patients enrolled into cohort A of treatment with single-agent envafolimab and more than 10 patients enrolled into cohort B of treatment with envafolimab and Yervoy ipilimumab for sarcoma, a rare group of cancers that arise in the bones and connective tissue. 